What did we learn from the OPTIMAAL trial? What can we expect from VALIANT?

American Heart Journal

Volumn 145, Issue 5, 2003, Pages 754-757

  Dickstein, Kenneth ^a  

^a UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II ANTAGONIST; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN; VALSARTAN;

DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; EDITORIAL; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HOSPITALIZATION; HUMAN; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RISK FACTOR; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0038066228     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(03)00168-6     Document Type: Editorial

References (23)

1. Dickstein K, Kjekshus J, the OPTIMAAL Trial Steering Committee. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002;360:752-60.
2. Pfeffer M, McMurray J, Leizorovicz A, et al. Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. Am Heart J 2000;140:727-34.
3. Pfeffer M. ACE inhibitors in acute myocardial infarction: patient selection and timing. Circulation 1998;97:2192-4.
4. Dickstein K, Kjekshus J, the OPTIMAAL Trial Steering Committee. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002;360:752-60.
5. Pitt B, Poole-Wilson P, Segal R, et al. Randomised trial of losartan versus captopril on mortality in patients with symptomatic heart failure: the losartan heart failure survival study-ELITE II. Lancet 2000;355:1582-7.
6. Tang W, Vagelos R, Yee Y, et al. Neurohumoral and clinical responses to high vs low-dose enalapril therapy in chronic heart failure. J Am Coll Cardiol 2002;39:70-8.
7. Gottleib S, Dickstein K, Fleck E, et al. Hemodynamic and neurohumoral effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation 1993;88:1602-9.
8. Latini R, Maggioni AP, Flather M, et al. ACE inhibitor use in patients with myocardial infarction: summary of evidence from clinical trials. Circulation 1995;92:3132-7.
9. Brenner B, Cooper M, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Eng J Med 2001;345:861-9.
10. Dahlöf B, Devereux RB, Kjeldsen S, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
11. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100 000 patients in randomised trials. Circulation 1998;97:2202-12.
12. Cohn JN, Tognoni G, for the Val-HeFT Investigators. Effect of the angiotensin blocker valsartan on morbidity and mortality in heart failure: the valsartan heart failure trial (Val-HeFT). N Engl J Med 2001;345:1667-75.
13. Maggioni A, Anand I, Gottlieb S, et al. Effets of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin converting enzyme inhibitors. J Am Coll Cardiol 2002;40:1414-21.
14. Valsartan approved for heart failure patients intolerant of ACE inhibitors. HeartWire News. Available at: http: www.theheart.org. Last accessed August 15, 2002.
15. Swedberg K, Pfeffer M, Granger G, et al. Candesartan in heart failure-assessment of reduction in mortality (CHARM): rationale and design. J Card Failure 1999;5:276-82.
16. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:812-28.
17. Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992;327:669-77.
18. Køber I, Torp-Pedersen C, Carlson JE, et al. A clinical trial of the angiotensin converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995;353:1670-6.
19. Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin converting enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995;332:80-5.
20. Abbas A, Rybicki B, Alam M, et al. Clinical predictors of heart failure in patients with first acute myocardial infarction. Am Heart J 1999;138:1133-9.
21. ISIS-4 Collaborative Group. ISIS-4: a randomized factorial trial assessing early oral captopril, oral mononitrate and intravenous magnesium sulfate in over 58,050 patients with suspected acute myocardial infarction. Lancet 1995;345:669-85.
22. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115-22.
23. Hall S, Sapsford R, Megary S, et al. Inhibition of the renin-angiotensin system after acute myocardial infarction: treat first, select later? Heart 1996;76:73-8.